Description:FIELD OF INVENTION
The present disclosure is related to development of synthetic chimeric antigen receptor (CAR) against CD19. Particularly, the present disclosure relates to designing of synthetic human anti-CD19 CAR which will be expressed by T cells. Particularly, the present disclosure relates to anti-CD19 CAR T cell therapy for B cell malignancies.
BACKGROUND OF INVENTION
Many patients with B-cell malignancies are incurable with conventional therapy, however traditional treatments often associate with serious side effects. Recent developments in cancer immunotherapy has overcome several challenges and have shown promising clinical outcomes. Genetically modified T cells expressing chimeric antigen receptors (CAR) administered in patients are designed to target specific antigen expressing malignant B cells such as CD19, and reported effective complete remission in patients with B-cell malignancies. CAR is engineered majorly with single chain variable fragment (scFv) linked with a hinge and transmembrane domain to one or more intracellular signaling domains. T cells isolated from patients will be modified to express CAR on their surface and redirected to target the antigen expressing tumor cells in hematologic and solid tumors.
Currently, there are 6 FDA approved CART therapies for the treatment of young and adults relapse/refractory B- ALL. Patients undergoing personalized CART cell therapy have shown improved remission and survival rate. However, existing CART therapies are associated with major drawbacks such as cytokine release syndrome, B cell aplasia, neurotoxicity etc. Hence, it’s important to carefully design the CAR construct to minimize toxic side effects and generate CART cells with longer persistence and reduced cytotoxicity. Hence, there’s a need for the development of specific antigen targeted CARs for the treatment of tumor malignancies with reduced toxicities, improved efficacy, higher stability and cost effective manufacturability.
SUMMARY OF INVENTION
In an embodiment, the invention provides a chimeric antigen receptor comprising (a) a promoter (b) leader sequence, (c) single chain variable fragment (scFv) as an antigen-specific targeting region, (d) a hinge region representing extracellular spacer domain, (e) a transmembrane domain, (f) at least one co- stimulatory signaling domain and (g) an intracellular signaling domain.
In an embodiment, the invention provides an antigen specific targeting region comprises a hu CD-19 specific single chain Fragment variable (scFv) fragment, that binds to the CD19 expressing malignant B cells.
In an embodiment, the anti CD-19 binding domain comprises a heavy chain from selected SEQ ID NO: 1 and 102 and a light chain of SEQ ID NO: 2 & 103.
In an embodiment, provides a peptide linker that connects the heavy chain and light chain of scFv and the encoded linker comprises an amino acid sequence of SEQ ID NO: 3 & nucleic acid sequence of 104
In an embodiment, the invention further provides a chimeric antigen receptor, comprising (a) a CD8a hinge extracellular spacer domain, (b) a CD8a transmembrane domain, (d) a cytoplasmic domain comprising a human CD27 and/or 4-1BB costimulatory domain and a CD3? intracellular signaling domain.
In an embodiment, a hinge domain connects the scFv with the transmembrane domain providing flexibility to the scFv domain for recognition of the target epitope. The hinge domain maintaining the optimal synapse distance comprises an amino acid sequence of SEQ ID NO: 5
In an embodiment, the transmembrane domain comprising the mRNA sequence from SEQ ID NO: 106 and amino acid sequence of SEQ ID NO: 5.
In an embodiment, the costimulatory domain comprises an amino acid sequence of SEQ ID NO: 6 & SEQ ID NO: 7 provides the signal for proliferation, metabolic cycles and activates transcription factors for the production of cytokines.
In an embodiment, recombinant nucleic acid sequence of hu anti-CD19 CAR comprising 4-1BB as costimulatory domain is selected from group of sequences of SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO:85, and SEQ ID NO:86.
In an embodiment, recombinant nucleic acid sequence of hu anti-CD19 CAR comprising CD27 as costimulatory domain is selected from group of sequences of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, and SEQ ID NO: 101.
In an embodiment, the intracellular signaling domain comprises an amino acid sequence of SEQ ID NO: 8.
In an embodiment, the promoter sequence for EF-1a and MND comprises an amino acid sequence of SEQ ID NO. 50, SEQ ID NO. 51, SEQ ID NO. 52, SEQ ID NO. 53, SEQ ID NO. 54, SEQ ID NO. 55, SEQ ID NO. 56, SEQ ID NO. 57, SEQ ID NO. 58, SEQ ID NO. 59, and SEQ ID NO. 60
In an embodiment, the B- cell malignancies such as B-cell chronic lymphocytic leukemia, acute lymphoblastic leukemia, B-cell non Hodgins lymphoma including other CD19 positive malignancies is selected for providing treatment using the present invention.
In a further aspect, this invention pertains to the nucleic acid molecule anti-CD19 CAR, for the treatment of CD-19 associated diseases.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1- (A&B) Synthetic construct of hu anti-CD19-4-1BBZ (KCAR) (C) schematic representation of the construct and (D) its predictive signaling network
Figure 2- (A&B) Synthetic construct of hu anti-CD19-CD27Z (LYSCAR) (C) schematic representation of the construct and (D) its predictive signaling network.
Figure 3- Table listing the Amino acid sequence of CDR regions in heavy chain and light chains in hu anti-CD19 CAR
Figure 4- Table listing the components of hu anti-CD19 CAR
Figure 5- Table listing the intracellular signaling domain of hu anti-CD19 CAR
Figure 6- Table listing the promoter sequence
DETAILED DESCRIPTION
All references cited herein are incorporated by reference in their entirety as though fully set forth. Unless defined, all the technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which invention belongs.
One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is not limited to the methods and/or materials and/or process parameters as provided in the following detailed description.
The present invention, the term hu as used herein, refers to nucleic acid or amino acid sequence derived proteins isolated from human.
The present invention provides details on development of a hu chimeric antigen receptor (CAR) where the recombinant nucleic acid molecule comprises a hu anti-CD19 binding domain, that targets highly conserved CD19 expressing B cell tumors as in case of B-cell malignancies including leukemia and lymphomas.
A CAR is engineered by connecting the extracellular domain, with one or more intracellular domain connected via a transmembrane domain. Based on the antigen targeted on cancer cells, extracellular domain has the antigen binding domain derived from a monoclonal antibody. The intracellular domain of CAR is derived from T cell receptors in cytoplasmic domain and primes the CAR expressing T cells against target antigen on extracellular domain. A transmembrane domain connects intracellular domain to extracellular domain, which is either derived naturally or designed as per requirements.
As described herein, the present invention comprises a hu CD19 binding domain provides anti-tumor activity against CD-19 expressing tumor cells. According to the present invention, the hu anti-CD19 chimeric antigen receptor is a polypeptide sequence, that comprises:
(a) A Signal sequence / leader sequence
(b) a scFv comprising a hu anti-CD19 binding domain
(c) a hinge region
(d) a transmembrane domain
(e) a co-stimulatory domain for CD27 and/or 41BB
(f) a CD3? intracellular signaling domain
(g) a promoter
Hu anti- CD19 domain
Current invention pertains to treat CD19 associated B cell malignancies where CD19 serves as an target antigen for the antigen binding domain in CAR. During maturation and development of B cells, they express various proteins on their surface and CD19 being one of them which is also expressed in most of the B cell malignancies but are absent in hematopoietic stem cells. Therefore, the cytotoxic effects are minimized by appropriate choice of antigens such as CD19. Anti CD19 CAR transduced into T cells are directed against the CD19 antigen expressing cells and effectively eliminate them without affecting the normal healthy cells. Majority of CARs developed till date have murine derived monoclonal antibody fragments as the antigen binding domain. The non-human origin CD-19 binding domain is present in most of the CAR-T cell products available commercially or in clinical trials which leads to immunogenicity of CAR-T cells. As a result, post infusion of engineered CAR expressing T cells are recognized as foreign antigen and triggers immune response to produce antibodies against CAR. Thus the non- human fragments in CAR is cleared prematurely hindering the efficacy of CAR-T cells and limited the repeat dosages. Therefore, hu anti-CD19 binding domain is designed from the fragment of KIG1 to obtain the single chain variable fragment (scFv) against the CD19 as known in prior art. Binding domains comprises of the complementarity determining regions (CDRs) and heavy and light chain frameworks as given in the figure 3. Usually, there are three CDRs namely CDR1, CDR2 and CDR3 which combined together forms a hypervariable region identifying the target antigen. Furthermore, the hu anti-CD19 CAR will overcome the obstacle of immunogenicity and minimize the adverse side effects of CAR-T cell product improving its efficacy and safety.
In the present invention, the hu anti- CD19 binding domain has heavy chain framework region of SEQ ID NO: 102 and Light chain framework region of SEQ ID NO: 103.
In another aspect, the hu anti- CD19 binding domain has heavy chain CDR1 (HC CDR1), heavy chain CDR2 (LC CDR2) and heavy chain CDR3 (HC CDR3) as shown in figure 3.
In further aspect, hu anti- CD19 binding domain (scFv) has a variable heavy chain region VH) and a variable light chain region (VL). VH of the scFv in the present invention is a polypeptide sequence represented by SEQ ID NO 1 having complementarity specific to T cells. Similarly, VL region is the amino acid sequence represented by SEQ ID NO: 2 figured to have high identity to framework regions of the human light chain and CDRs sequence.
In another aspect, the hu anti- CD19 binding domain has light chain CDR1 (LC CDR1), light chain CDR2 (LC CDR2) and light chain CDR3 (LC CDR3) as shown in figure 3.
In the present invention, the leader sequence at the amino terminal is an amino acid sequence of SEQ ID NO: 4 and is encoded by the mRNA sequence selected from SEQ ID NO: 105 or mRNA sequence with at least 95% identity from the parent SEQ ID NO:105.
Hinge and Transmembrane domain
The antigen binding domain of CAR is connected to the transmembrane domain via a hinge region. The hinge region is derived from CD8a similar to the prior art. Anchorage between extracellular domain and intracellular domain is facilitated by the transmembrane domain in the synthetic CAR construct developed in the present invention. Generally, the transmembrane domain is chosen from type I proteins such as CD3?, CD28, CD8a and also other T cell related molecules.
In the present invention, transmembrane domain derived from human CD8a comprises of amino acid sequence of SEQ ID NO: 5.
Co-stimulatory and intracellular signaling domain
Intracellular domain of the synthetic CAR construct in present invention has two domains, viz., co-stimulatory domain and intracellular signaling domain derived from cytoplasmic domains of T cells receptor complex. Effector function and anti-tumor activity is influenced by the choice of intracellular domain and expressed by the cells encoding the CAR majorly T cells expressing CAR. In one embodiment, the cytoplasmic domain is derived from human CD3? comprising of amino acid sequences as in figure 4.
In another embodiment, the amino acid and nucleic sequence for recombinant synthetic CAR construct comprising human 4-1BB and or CD27 as co-stimulatory domain is selected from figure 5.
In another embodiment, the human EF-1a and MND promoter sequences are selected from the figure 6.
The inclusion of the 4-1BB co-stimulatory domain in the CAR structure enhances the persistence, proliferation, and anti-tumor activity of CAR-T cells. Co-stimulation through 4-1BB provides an additional signal that complements the primary activation signal delivered by the TCR, leading to more robust and sustained T-cell activation. The activation of 4-1BB also plays a role in the regulation of certain cytokines and immune mediators, further influencing the overall T-cell response. CD27 has been reported to activate the non-canonical NF-?B signaling pathway through its interaction with TRAF2. CD27 signaling plays a role in enhancing T-cell and B-cell activation, proliferation, and differentiation by production of cytokines and effector molecules, which are critical for mounting an effective immune response against pathogens or antigens. It can also influence apoptosis through several mechanisms, including the regulation of caspase activity and the expression of pro-survival or pro-apoptotic molecules. This pathway is critical for supporting the metabolic demands of activated immune cells and maintaining their long-term survival, particularly in memory T cell development.
In another embodiment, the co-stimulatory domain of cytoplasmic domain is derived from human 4-1BB is labelled as KCAR in the present invention and encoded by mRNA sequence selected from group of sequences of SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83 , SEQ ID NO: 84, SEQ ID NO: 85 and SEQ ID NO: 86 or a mRNA sequence with at least 95% identity to an mRNA sequence provided in SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83 , SEQ ID NO: 84, SEQ ID NO: 85 and SEQ ID NO: 86 thereof.
In another embodiment, the co-stimulatory domain of cytoplasmic domain is derived from human CD27 is labelled as LYSCAR in the present invention and encoded by mRNA sequence selected from group of sequences of SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO:100 and SEQ ID NO: 101 or a mRNA sequence with at least 95% identity to an mRNA sequence provided in SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO:100 and SEQ ID NO: 101 thereof. , Claims:We claim:
1. A nucleic acid encoding huCAR is claimed, wherein CAR comprises;
(h) A Signal sequence / leader sequence
(i) A scFv or fragment comprising a hu anti- CD19 binding domain
(j) A hinge region
(k) A transmembrane domain
(l) A cytoplasmic domain comprising at least one co-stimulatory domain and
(m) One intracellular signaling domain
Wherein each antigen targeting domain comprises an antigen- specific single chain fragment Fv (scFv) fragment, a heavy chain framework region, a light chain framework region.
(m) A promoter sequence EF-1a & MND
2. The ORF3 of huCAR encoding the nucleic acid & amino acid sequences huanti-CD19 CAR T-cell therapy for antigen binding domains, directed to B cell malignancies as in claim 1 comprises of sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, and SEQ ID NO: 109.
3. A synthetic construct CAR is the nucleic acid sequence encoding amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO: 50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59 and SEQ ID NO: 60.
4. A Synthetic construct CAR sequence claimed in claim 3, which encodes amino acid sequence for heavy chain variable region (HCVR) of SEQ ID NO: 1 and a light chain variable determining region (LCVR) of SEQ ID NO: 2.
5. A Synthetic construct CAR of claim 4, which encodes for heavy chain complementary determining region (HC CDR1) of SEQ ID NO: 102 and a light chain complementary determining region (LC CDR1) of SEQ ID NO: 103.
6. A Synthetic construct CAR claimed in any of the preceding claims, which encodes heavy chain complementary determining region (HC CDR2) of SEQ ID NO: 102 and a light chain complementary determining region (LC CDR2) of SEQ ID NO: 103.
7. A Synthetic construct CAR claimed in any of the preceding claims, which encodes heavy chain complementary determining region (HC CDR3) of SEQ ID NO: 102 and a light chain complementary determining region (LC CDR3) of SEQ ID NO: 103.
8. A Synthetic construct CAR sequence as claimed in any of the preceding claims, wherein the heavy chain variable region (HCVR) and the light chain variable region (LCVR) comprises an amino acid sequence having at least one, two or three modifications but not more than 10/ 20 modifications of an amino acid sequence or a sequence with 95- 99 % identity to an amino acid sequence of SEQ ID NO 1 and SEQ ID NO: 2 thereof.
9. A Synthetic construct CAR sequence as claimed in of any of the preceding claims, wherein the encoded HCVR is attached to the encoded LCVR via a linker.
10. A Synthetic construct CAR sequence as claimed in claim 9, wherein the encoded linker comprises an amino acid sequence of SEQ ID NO: 3.
11. A Synthetic construct CAR sequence of any of the preceding claims, wherein the encoded CAR includes a transmembrane domain of a protein derived from a human CD8a.
12. A Synthetic construct CAR sequence as of claim 11, wherein the encoded transmembrane domain comprises a sequence of SEQ ID NO: 5 or a sequence with 95-99% identity thereof.
13. A Synthetic construct CAR sequence of any of the preceding claims, wherein the encoded anti-CD19 binding domain is connected to the transmembrane domain by a hinge region.
14. A Synthetic construct CAR molecule of claim 13, wherein the encoded hinge region comprises a amino acid sequence of the SEQ ID NO: 5 or a sequence with 95-99 % identity thereof.
15. A Synthetic construct CAR sequence of any of the preceding claims, wherein further comprises a costimulatory domain is a functional signaling domain derived from a human of a protein selected from group consisting of one or more of 4-1BB, CD27, NFAT, Sirtuin1 (SIRT1) and ICAM1
16. A Synthetic construct CAR molecule of claim 2, wherein the encoded costimulatory domain for 41BB (KCAR) is selected from amino acid sequences of SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34, or a sequence with 95-99% identity to an amino acid sequence provided of SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34 thereof.
17. A Synthetic construct CAR molecule of claim 2, wherein the encoded costimulatory domain for CD27 (LYSCAR) comprises a sequence of SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49 or a sequence with 95-99% identity to an amino acid sequence provided in SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49 thereof.
18. A Synthetic construct CAR of any of the preceding claims, wherein the encoded co stimulatory domain comprises a signaling domain from human CD3? chain.
19. A Synthetic construct CAR molecule of any of the preceding claims, wherein the encodes an mRNA sequence for intracellular signaling domain of the SEQ ID NO: 109 or a sequence with 95-99 % identity thereof.
20. A Synthetic construct CAR as claimed in claim 2, wherein the encoded hu anti-CD19 CAR further comprises a leader sequence.
21. The nucleic acid molecule as claimed in claim 20, wherein the leader sequence comprises the amino acid sequences of SEQ ID NO: 4.
22. A Synthetic construct CAR as claimed in any of claims 1 to 21, wherein it comprises a nucleic acid sequence optimized for human codon usage.
23. A synthetic construct CAR comprising ORF3 encodes the anti-CD19 CAR of claim 2 or the combination of any of the preceding claims.
24. A synthetic construct CAR as claimed in any of the above claims 1 to 21, wherein it comprises a promoter EF-1a and MND of amino acid sequence of SEQ ID NO. 50, SEQ ID NO. 51, SEQ ID NO. 52, SEQ ID NO. 53, SEQ ID NO. 54, SEQ ID NO. 55, SEQ ID NO. 56, SEQ ID NO. 57, SEQ ID NO. 58, SEQ ID NO. 59, and SEQ ID NO. 60 or a sequence with 95-99% identity to an amino acid sequence provided in SEQ ID NO. 50, SEQ ID NO. 51, SEQ ID NO. 52, SEQ ID NO. 53, SEQ ID NO. 54, SEQ ID NO. 55, SEQ ID NO. 56, SEQ ID NO. 57, SEQ ID NO. 58, SEQ ID NO. 59, and SEQ ID NO. 60, thereof.
25. A synthetic CAR construct is claimed to treating a subject having a disease associated with expression of a CD19, comprising administering to the subject an effective quantity of an immune effector cells according to claim 23.